Recent Patents on Anti-Cancer Drug Discovery This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

NIFK, a Potential Prognostic and Immunological Biomarker in Pan-- Cancer Analysis, Significantly Regulates Proliferation and Metastasis of Colorectal Cancer
CONCLUSION: The results of this study demonstrated that NIFK, as a member of the pan-cancer genes, will serve as a biomarker and a potential therapeutic target for a range of cancer types, providing new insight into precision medicine.PMID:38659266 | DOI:10.2174/0115748928295346240406185103 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 25, 2024 Category: Cancer & Oncology Authors: Zhuoyuan Li Shangbo Zhou Ting Bin Yuntao Shi Leli Zeng Bo Li Jia Li Yulong He Changhua Zhang Source Type: research

Sema3A Inhibits Osteolytic Bone Metastasis of Non-small Cell Lung Cancer
CONCLUSION: This study provides a new idea for the clinical treatment of osteolytic bone metastasis in NSCLC.PMID:38629364 | DOI:10.2174/0115748928295263240402085411 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Wei Wang Kaicheng Shen Ruyan Liu Qi Zhou Source Type: research

Eukaryotic Initiation Factor 3C Can Affect the Proliferation and Invasion of Ovarian Cancer by Regulating the p53 Signalling Pathway
CONCLUSION: There is a correlation between overexpression of EIF3C in tumour tissues of ovarian cancer patients and this is associated with a poorer prognosis. By influencing the p53 signaling pathway, EIF3C facilitates the growth and infiltration of cells in ovarian cancer.PMID:38629365 | DOI:10.2174/0115748928292248240401051408 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Jingkaiwen Zhang Hanlin Yang Fang Wen Qing Li Hao Luo Dan Zi Source Type: research

Sema3A Inhibits Osteolytic Bone Metastasis of Non-small Cell Lung Cancer
CONCLUSION: This study provides a new idea for the clinical treatment of osteolytic bone metastasis in NSCLC.PMID:38629364 | DOI:10.2174/0115748928295263240402085411 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Wei Wang Kaicheng Shen Ruyan Liu Qi Zhou Source Type: research

Eukaryotic Initiation Factor 3C Can Affect the Proliferation and Invasion of Ovarian Cancer by Regulating the p53 Signalling Pathway
CONCLUSION: There is a correlation between overexpression of EIF3C in tumour tissues of ovarian cancer patients and this is associated with a poorer prognosis. By influencing the p53 signaling pathway, EIF3C facilitates the growth and infiltration of cells in ovarian cancer.PMID:38629365 | DOI:10.2174/0115748928292248240401051408 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Jingkaiwen Zhang Hanlin Yang Fang Wen Qing Li Hao Luo Dan Zi Source Type: research

Sema3A Inhibits Osteolytic Bone Metastasis of Non-small Cell Lung Cancer
CONCLUSION: This study provides a new idea for the clinical treatment of osteolytic bone metastasis in NSCLC.PMID:38629364 | DOI:10.2174/0115748928295263240402085411 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Wei Wang Kaicheng Shen Ruyan Liu Qi Zhou Source Type: research

Eukaryotic Initiation Factor 3C Can Affect the Proliferation and Invasion of Ovarian Cancer by Regulating the p53 Signalling Pathway
CONCLUSION: There is a correlation between overexpression of EIF3C in tumour tissues of ovarian cancer patients and this is associated with a poorer prognosis. By influencing the p53 signaling pathway, EIF3C facilitates the growth and infiltration of cells in ovarian cancer.PMID:38629365 | DOI:10.2174/0115748928292248240401051408 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Jingkaiwen Zhang Hanlin Yang Fang Wen Qing Li Hao Luo Dan Zi Source Type: research

Sema3A Inhibits Osteolytic Bone Metastasis of Non-small Cell Lung Cancer
CONCLUSION: This study provides a new idea for the clinical treatment of osteolytic bone metastasis in NSCLC.PMID:38629364 | DOI:10.2174/0115748928295263240402085411 (Source: Recent Patents on Anti-Cancer Drug Discovery)
Source: Recent Patents on Anti-Cancer Drug Discovery - April 17, 2024 Category: Cancer & Oncology Authors: Wei Wang Kaicheng Shen Ruyan Liu Qi Zhou Source Type: research